Immunotherapy for autoimmune and inflammatory renal diseases.
Immune-mediated renal disease (IMRD) accounts for 20 - 30% of the cases of end stage renal failure. It frequently occurs in the context of multi-system autoimmune disorders, including systemic lupus erythematosus (SLE) and primary systemic vasculitis. Current therapies are partially effective and comprise the combination of steroids with an immunosuppressive, such as cyclophosphamide. Their toxicity contributes to the morbidity and mortality of these disorders, and long-term treatment is necessary to prevent relapse. There is a clear need for better-targeted, more effective and less toxic therapy. Advances in our understanding of the immunopathogenesis of inflammatory autoimmune renal disease have identified potential targets for newer agents and have improved the monitoring of therapeutic responses. Recent experience with newer therapies in IMRD is reviewed. This has typically involved small, non-randomised, open-label trials and has addressed reversible features of disease activity. Larger, randomised comparisons to standard therapy are needed along with assessment of long-term efficacy and safety.
Booth
Anthony D
AD
Department of Renal Medicine (Box 118), Addenbrooke's Hospital, Hills Rd, Cambridge, CB2 2QQ, UK.
Firth
John D
JD
Jayne
David R W
DR
D000818:Animals; D001327:Autoimmune Diseases / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007249:Inflammation / Q000188:drug therapy / Q000276:immunology; D007674:Kidney Diseases / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology*; D009393:Nephritis / Q000188:drug therapy / Q000276:immunology / Q000473:pathology*